Scholarlink

<p>Lemborexant, a dual orexin receptor antagonist, is approved in multiple countries, including the USA, Canada, Australia, Japan and several others in Asia, for treating insomnia in adults. Its efficacy was demonstrated in the 12-month phase 3 SUNRISE-2 trial in adults with insomnia disorder. This Adis Summary of Research reports findings from a post hoc subgroup analysis of adults aged ≥ 65 years in SUNRISE-2.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adis Summary of Research: Efficacy of lemborexant in adults ≥ 65 years of age with insomnia disorder

  • 期刊论文

  • 发表日期：

    2025年8月11日

查看全文
  • Yahiya Y. Syed

摘要

Lemborexant, a dual orexin receptor antagonist, is approved in multiple countries, including the USA, Canada, Australia, Japan and several others in Asia, for treating insomnia in adults. Its efficacy was demonstrated in the 12-month phase 3 SUNRISE-2 trial in adults with insomnia disorder. This Adis Summary of Research reports findings from a post hoc subgroup analysis of adults aged ≥ 65 years in SUNRISE-2.